Global News and Digital Insights
for the Healthcare Industry

RapidAI’s AI technology for pulmonary embolism diagnosis gets a nod from FDA

The FDA cleared RapidAI’s technology, which is devised to identify pulmonary embolism, a deadly disease initiated by a clot deep in the body, otherwise known as deep vein thrombosis. The system will assist in an earlier diagnosis of pulmonary embolism, allowing treatment at initial stages. The California-based firm’s FDA-approved AI system, Rapid PE Triage & Notification, will detect a suspected pulmonary embolism present anywhere in the lung arteries. After detection, the physician will automatically be notified about the existence of a suspected clot through the system, thereby reducing the time to provide triage and care to the patient. The goal is to take a patient’s care as early and quickly as possible.

Read More from Medcity News

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn